Pages that link to "Q84443876"
Jump to navigation
Jump to search
The following pages link to Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion (Q84443876):
Displaying 33 items.
- PD-L1 expression in human cancers and its association with clinical outcomes (Q26738361) (← links)
- The prognostic value of liver tumor T cell infiltrates (Q34052611) (← links)
- Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade (Q35184928) (← links)
- Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories (Q36587186) (← links)
- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma (Q37630808) (← links)
- Dual roles for immunity in gastrointestinal cancers (Q37774172) (← links)
- Aberrant DNA methylation profile in cholangiocarcinoma (Q37878880) (← links)
- Emerging molecular targets and therapy for cholangiocarcinoma (Q38642455) (← links)
- PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. (Q38642853) (← links)
- Immunotherapy of biliary tract cancer (Q38686339) (← links)
- Immunotherapeutic Approaches to Biliary Cancer (Q38703148) (← links)
- The case for immune-based approaches in biliary tract carcinoma (Q38833922) (← links)
- The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism (Q38948330) (← links)
- Emerging molecular therapeutic targets for cholangiocarcinoma (Q39227356) (← links)
- Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors (Q39245977) (← links)
- Treating Hepatobiliary Cancer: The Immunologic Approach (Q39280840) (← links)
- Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers (Q39389346) (← links)
- Immunotherapy in gastrointestinal cancers (Q39453597) (← links)
- PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma (Q40977436) (← links)
- Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. (Q52676017) (← links)
- Targeting cholangiocarcinoma. (Q52757760) (← links)
- Immune checkpoint therapy in liver cancer. (Q55008806) (← links)
- Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma. (Q55262931) (← links)
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) (Q57118798) (← links)
- The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium (Q59133892) (← links)
- Biliary tract cancers: current knowledge, clinical candidates and future challenges (Q64101426) (← links)
- Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials (Q64249982) (← links)
- Küpffer Cells Promote Acute Rejection via Induction of Th17 Differentiation in Rat Liver Allografts (Q82540786) (← links)
- Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma (Q88435903) (← links)
- Immunobiology of cholangiocarcinoma (Q89624031) (← links)
- The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives (Q91654978) (← links)
- Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors (Q92324220) (← links)
- Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers (Q92716614) (← links)